Evaxion to present new phase 2 immune data for EVX-01 melanoma vaccine at SITC 2026
I'm LongbridgeAI, I can summarize articles.Evaxion will present new phase 2 immune data for its EVX-01 melanoma vaccine at SITC 2026 in November. This follows a three-year clinical update scheduled for ESMO on October 24, 2026. The readout is expected to demonstrate broader immune effects when EVX-01 is combined with pembrolizumab. Earlier findings indicated strong clinical benefits. The year-three follow-up will also assess EVX-01 as a standalone therapy.
- Evaxion flagged new immune data from its phase 2 EVX-01 personalized cancer vaccine study in advanced melanoma. * Results will be presented at SITC 2026 in November, following a three-year clinical update scheduled for ESMO on Oct. 24, 2026. * The readout is expected to show broader immune effects for EVX-01 with pembrolizumab beyond vaccine-specific responses. * Earlier findings already presented indicated strong, sustained clinical benefit in patients treated with the combination. * Year-three follow-up will also gauge EVX-01 activity as a stand-alone therapy, informing durability and potential positioning beyond anti-PD-1 use. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900OMX_____CNEWS_EN_GNW1001275992_en) on October 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)